165 related articles for article (PubMed ID: 31848332)
1. A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2.
Tamura R; Fujioka M; Morimoto Y; Ohara K; Kosugi K; Oishi Y; Sato M; Ueda R; Fujiwara H; Hikichi T; Noji S; Oishi N; Ogawa K; Kawakami Y; Ohira T; Yoshida K; Toda M
Nat Commun; 2019 Dec; 10(1):5758. PubMed ID: 31848332
[TBL] [Abstract][Full Text] [Related]
2. Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
Tamura R; Morimoto Y; Kosugi K; Sato M; Oishi Y; Ueda R; Kikuchi R; Nagashima H; Hikichi T; Noji S; Kawakami Y; Sasaki H; Yoshida K; Toda M
BMC Cancer; 2020 Mar; 20(1):196. PubMed ID: 32164575
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
Farschtschi S; Merker VL; Wolf D; Schuhmann M; Blakeley J; Plotkin SR; Hagel C; Mautner VF
Acta Neurol Scand; 2016 Jun; 133(6):475-80. PubMed ID: 26369495
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors.
Tamura R; Sato M; Morimoto Y; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Murase M; Yoshida K; Toda M
Exp Mol Pathol; 2020 Jun; 114():104408. PubMed ID: 32088190
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.
Hayashi H; Kurata T; Fujisaka Y; Kawakami H; Tanaka K; Okabe T; Takeda M; Satoh T; Yoshida K; Tsunoda T; Arao T; Nishio K; Nakagawa K
Cancer Sci; 2013 Jan; 104(1):98-104. PubMed ID: 23020774
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
[TBL] [Abstract][Full Text] [Related]
9. Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer.
Murahashi M; Tsuruta T; Yamada K; Hijikata Y; Ogata H; Kishimoto J; Yoshimura S; Hikichi T; Nakanishi Y; Tani K
Anticancer Res; 2021 Mar; 41(3):1485-1496. PubMed ID: 33788741
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
[TBL] [Abstract][Full Text] [Related]
11. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities.
Sverak P; Adams ME; Haines SJ; Levine SC; Nascene D; Sommer K; Dusenbery K; Huang TC; Moertel C
Otolaryngol Head Neck Surg; 2019 Mar; 160(3):526-532. PubMed ID: 30373466
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
Sponghini AP; Platini F; Rondonotti D; Soffietti R
Tumori; 2015 Nov; 101(6):e167-70. PubMed ID: 26108240
[TBL] [Abstract][Full Text] [Related]
14. Multiplexing Angiogenic Receptor Quantification via Quantum Dots.
Chen S; Imoukhuede PI
Anal Chem; 2019 Jun; 91(12):7603-7612. PubMed ID: 31088078
[TBL] [Abstract][Full Text] [Related]
15. Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.
Tamura R; Morimoto Y; Sato M; Kuranari Y; Oishi Y; Kosugi K; Yoshida K; Toda M
J Neurooncol; 2020 Jan; 146(2):265-273. PubMed ID: 31897926
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
[TBL] [Abstract][Full Text] [Related]
17. Stemline's synthetic multi-peptide cancer vaccine enters Phase 2.
Riedmann EM
Hum Vaccin Immunother; 2014; 10(6):1430. PubMed ID: 25396232
[No Abstract] [Full Text] [Related]
18. Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas.
Baumgarten P; Brokinkel B; Zinke J; Zachskorn C; Ebel H; Albert FK; Stummer W; Plate KH; Harter PN; Hasselblatt M; Mittelbronn M
Histol Histopathol; 2013 Sep; 28(9):1157-66. PubMed ID: 23475388
[TBL] [Abstract][Full Text] [Related]
19. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
[TBL] [Abstract][Full Text] [Related]
20. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11
Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Naitou M; Sasada T; Hattori N; Kohno N; Itoh K
Cancer Sci; 2017 Apr; 108(4):598-603. PubMed ID: 28178396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
